Skip to content
1 min left · finish 2:17 AM
Email
Sydney
Sydney
Meridan ReportSydney: Australian finance, Asia-Pacific tech bridge
Good evening, Columbus⛅63°F · Cloudy
BusinessTechnologyCommunitySchoolsGovernmentSportsReal EstateDiningArtsHealthSaved

Advertisement · Why this ad?

  1. Home
  2. /Health
  3. /Drug maker Rohto plans clinical trials in Hong Kong as OASES’ first Japan partner
Health

Drug maker Rohto plans clinical trials in Hong Kong as OASES’ first Japan partner

Katherine Langford
Katherine Langford
Katherine Langford
Editor-in-Chief · Edina, MN

Katherine oversees editorial operations across all six brands. Before joining The Meridan Group, she spent 14 years at the Minneapolis Star Tribune, where she led the metro desk through its digital transformation. She holds a Master's in Journalism from Northwestern's Medill School.

More from Katherine →
Editor-in-Chief · Monday, November 2, 2026 at 12:30 AM · 1 min read
Text size
Typeface
Line spacing
Theme
Focus mode
Email
Drug maker Rohto plans clinical trials in Hong Kong as OASES’ first Japan partner — Sydney Health news

Top university research, cross-border data exchanges and access to mainland China’s large market have attracted Japanese firm Rohto Pharmaceutical to conduct clinical trials in Hong Kong, making it the first company from the country to partner with the city’s government under a flagship investment initiative. Rohto, known for its over-the-counter eye care and skincare products, is among the latest batch of 18 firms recruited by the Office for Attracting Strategic Enterprises (OASES), a...

Up nextHow could a single gene-editing injection treat inherited eye diseases?Health · 1 min read

More Health stories

How could a single gene-editing injection treat inherited eye diseases? — South China Morning Post
Health

How could a single gene-editing injection treat inherited eye diseases?

By Marcus Chen

Ex-Japanese adult film actress in intensive care after alleged drugging in Hong Kong — South China Morning Post
Health

Ex-Japanese adult film actress in intensive care after alleged drugging in Hong Kong

By Katherine Langford

‘Be alive’: Hongkonger with muscular dystrophy turns 18, against all odds — South China Morning Post
Health

‘Be alive’: Hongkonger with muscular dystrophy turns 18, against all odds

By Katherine Langford

Hongkongers need more than 4 walls and a roof to make a home — South China Morning Post
Health

Hongkongers need more than 4 walls and a roof to make a home

By Katherine Langford

Also covering Global

RiyadhNew YorkSan FranciscoLos AngelesBoston

Meridan Report — Sydney

Part of the Meridan Report Network

Sydney: Australian finance, Asia-Pacific tech bridge. Finance, AI, and technology intelligence across 40 global cities.

Sections

BusinessTechnologyCommunitySchoolsGovernmentSports

Latest Stories

Drug maker Rohto plans clinical trials in Hong Kong as OASES’ first Japan partnerHumans vs AI art: why game studios hire Southeast Asian talentKPMG set to slash hundreds more jobs before ChristmasJoshua Cooper Ramo on whether the US can handle the stress test of China’s risePrivate jet carrying 9 crashes into Florida roadside, erupting in a massive fireball

About

Meridan Report delivers institutional-grade intelligence on finance, AI, and technology from 40 global markets.

RSS FeedNetwork Directory

© 2026 Meridan Report — meridanreport.com

PrivacyTerms

A product of Edina Automation LLC

You're offline — showing the last loaded page
HomeSearchSaved